Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
相关临床试验
18
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
44.4%
已完成
6
33.3%
尚未招募
1
5.6%
招募中
1
5.6%
终止
1
5.6%
撤回
1
5.6%
暂无批准数据
- The Waldenström macroglobulinemia treatment market across the 7MM is expected to grow steadily through 2036, driven by rising diagnosis rates, aging populations, and adoption of targeted therapies. - Emerging agents including nemtabrutinib, bexobrutideg (NX-5948), and iopofosine I-131 aim to address relapsed/refractory disease and overcome resistance to covalent BTK inhibitors. - Cellectar's iopofosine I-131 achieved an 83.6% overall response rate and 61.8% major response rate in the Phase IIb CLOVER-WaM trial, with a median duration of response of 17.8 months. - The United States accounted for the largest Waldenström macroglobulinemia treatment market share in the 7MM in 2025, with an incidence of roughly 3 cases per million annually.
- Cellectar Biosciences plans to submit a Conditional Marketing Authorization application to the European Medicines Agency for iopofosine I 131 in Waldenström's macroglobulinemia in Q3 2026, with potential approval in early 2027. - The FDA has granted Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory Waldenström's macroglobulinemia and confirmed an accelerated approval pathway. - The company will begin dosing patients in a Phase 1b study of CLR 125 for triple-negative breast cancer in Q1 2026, with interim data expected mid-2026. - Iopofosine I 131 has received multiple regulatory designations including six Orphan Drug, five Rare Pediatric Drug, and two Fast Track Designations from the FDA.
- Cellectar Biosciences announced a strategic multi-year supply agreement with Ionetix Corporation for clinical and commercial-scale production of Actinium-225 and Astatine-211 radioisotopes. - The agreement supports development of CLR-225, a phospholipid radioconjugate targeting challenging solid tumors including pancreatic cancer, advancing the company's targeted alpha therapy pipeline. - Ionetix is installing a second cyclotron at its Michigan facility to meet growing demand, with dedicated production lines for each alpha-emitting isotope. - The collaboration leverages Cellectar's proprietary phospholipid ether platform technology, which delivers isotopes directly to tumor cells while sparing healthy tissue.
- Cellectar Biosciences secured approximately $5.8 million in gross proceeds through institutional investor warrant exercises, with Ladenburg Thalmann serving as exclusive placement agent. - The funding will support the company's Phase 1b clinical study of CLR 121125 in triple-negative breast cancer and preparation for European regulatory filing. - The company's proprietary Phospholipid Drug Conjugate platform targets next-generation cancer treatments with improved efficacy and safety profiles. - Cellectar's lead asset iopofosine I 131 has received six Orphan Drug, four Rare Pediatric Drug, and two Fast Track designations from the FDA.
- Cellectar Biosciences has partnered with Evestia Clinical to conduct a Phase 1b clinical trial evaluating CLR 125, an iodine-125 Auger-emitting radiopharmaceutical, for treating triple-negative breast cancer. - The trial will be conducted at a Mayo Clinic Network site with Dr. Pooja Advani as lead investigator, leveraging Evestia's expanded oncology expertise following its merger with Atlantic Research Group. - Triple-negative breast cancer affects approximately 12% of breast cancer patients in the U.S., with about 25% experiencing relapse after standard treatments, highlighting the critical need for innovative targeted therapies. - CLR 125 represents part of Cellectar's proprietary Phospholipid Drug Conjugate platform designed to deliver improved efficacy and safety through targeted cancer cell delivery with fewer off-target effects.
- DelveInsight's 2025 report reveals over 165 companies are developing 170+ pipeline therapies for triple-negative breast cancer, driven by rising disease prevalence and growing research investments. - Recent clinical milestones include Cardiff Oncology's positive Phase 1b data for onvansertib plus paclitaxel, Akeso's breakthrough therapy designation for ivonescimab combination, and multiple Phase III studies initiated by AstraZeneca and others. - Leading pipeline candidates include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), representing diverse therapeutic approaches from CDK4/6 inhibitors to antibody-drug conjugates. - The TNBC therapeutics market is expected to undergo substantial growth due to improved diagnostics, increased awareness, higher healthcare spending, and anticipated launches of innovative treatments.
- Cellectar Biosciences has submitted a Phase 1b dose-finding study protocol to the FDA for CLR 125, an iodine-125 Auger-emitting radiopharmaceutical targeting relapsed triple-negative breast cancer. - The study will evaluate three different dosing regimens in 45 patients, utilizing imaging to determine tumor uptake and establish the recommended Phase 2 dose. - CLR 125 leverages Cellectar's proprietary Phospholipid Drug Conjugate platform to deliver targeted radiation therapy with enhanced cytotoxicity and improved safety profile. - Triple-negative breast cancer represents approximately 12% of breast cancer diagnoses in the U.S., with 25% of cases relapsing after standard treatments, creating significant unmet medical need.
- Cellectar Biosciences reported that iopofosine I 131 achieved 5.4 months average progression-free survival in pediatric high-grade glioma patients, doubling the reported median of 2.25 months. - Patients receiving higher doses (minimum 55 mCi) showed 8.6 months overall survival, with three patients receiving additional cycles achieving 11.5 months average overall survival. - The radioligand therapy demonstrated a favorable safety profile with no cardiovascular, renal, or liver toxicities, and all hematologic adverse events were manageable and reversible. - The CLOVER-2 Phase 1 trial enrolled 14 pediatric patients with relapsed/refractory high-grade gliomas, including diffuse midline gliomas and diffuse intrinsic pontine gliomas.
- Cellectar Biosciences secured $2.5 million in funding through the exercise of existing warrants at a reduced price of $0.3041 per share, with proceeds designated for general corporate purposes and operating expenses. - The company's lead candidate iopofosine I 131 has received FDA Breakthrough Therapy Designation and is being studied in Phase 2b trials for multiple myeloma and CNS lymphoma. - Cellectar's proprietary Phospholipid Drug Conjugate platform aims to deliver next-generation cancer treatments with improved efficacy and safety through targeted delivery mechanisms.
- Cellectar Biosciences plans to highlight its 2025 strategic initiatives at the Biotech Showcase during the JP Morgan Healthcare Conference. - The CLOVER-WaM study showed Iopofosine I 131 achieved an 83.6% overall response rate in relapsed/refractory Waldenstrom's Macroglobulinemia. - Cellectar is advancing radiotherapeutic assets, including CLR 121225 and CLR 121125, into Phase 1/2a solid tumor studies. - The company is working towards FDA accelerated approval and EMA Prime marketing authorization for Iopofosine I 131.
